Scholar Rock Holding Stock News

Scholar Rock Holding Corp (NASDAQ: SRRK ) announced the study design for the SAPPHIRE Phase 3 trial of apitegromab, a selective inhibitor of the activation of latent myostatin. The trial will evaluate the efficacy and safety of apitegromab in patients with non-ambulatory Type 2 and Type 3 spinal muscular atrophy (SMA). Study start-up activities for SAPPHIRE have commenced. Approximately 156 patients aged 2-12 years old with non-ambulatory Type 2/3 SMA will be enrolled in the primary efficacy population. Patients will Full story available on Benzinga.com

Credit Suisse AG reduced its stake in shares of Scholar Rock Holding Co. (NASDAQ:SRRK) by 9.2% in the second quarter, according to its most recent filing with the SEC. The fund owned 13,264 shares of the companys stock after selling 1,345 shares during the period. Credit Suisse AGs holdings in Scholar Rock were worth $383,000 []

Scholar Rock Holding Corporation (NASDAQ:SRRK) shares, rose in value on Friday, 11/26/21, with the stock price down by -0.95% to the previous days close as strong demand from buyers drove the stock to $26.97. Actively observing the price movement in the last trading, the stock closed the session at $27.23, falling within a range of Thinking Of Selling Scholar Rock Holding Corporation (NASDAQ: SRRK) Stock? Read This First. Read More »

Millennium Management LLC lifted its position in Scholar Rock Holding Co. (NASDAQ:SRRK) by 325.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 173,839 shares of the companys stock after acquiring an additional 132,956 shares during the period. Millennium Management LLC owned 0.50% of Scholar Rock []

Piper Sandler initiated coverage on shares of Scholar Rock (NASDAQ:SRRK) in a research report sent to investors on Thursday morning, Analyst Ratings Network reports. The brokerage issued an overweight rating and a $56.00 target price on the stock. SRRK stock opened at $29.54 on Thursday. The company has a market capitalization of $1.04 billion, a []

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -20.00% and 24.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announces an e-poster presentation of clinical results from the TOPAZ Phase 2 trial at the 25th World Congress of Neurology (WCN).

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced that the USPTO issued U.S. Patent No. 11,130,803, with projected expiry of May 2040, providing product protection for SRK-181.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock is announcing two poster presentations as part of the World Muscle Society (WMS) Virtual Congress taking place September 20-24, 2021.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundament

New York, New York--(Newsfile Corp. - August 17, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation ("Scholar Rock" or the "Company") (NASDAQ: SRR

NEW YORK, Aug. 11, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation ("Scholar Rock" or the "Company") (NASDAQ: SRRK). Such inve

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -7.69% and -13.89%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for

New York, New York--(Newsfile Corp. - August 9, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation ("Scholar Rock" or the "Company") (NASDAQ: SRRK

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundament